Introduction
In the West, renal cell cancer accounts for 2% of all and 1993.6 This failure of chemotherapy could be explained by the high levels of expression of the cancers. Over 4000 new cases are currently reported multi-drug resistance gene in renal tumours.7 Two annually in the UK1 and a worldwide mortality in highly homologous genes, MDR1 and MDR2, located excess of 100 000 deaths is predicted in the on the long arm of chromosome 7, encode for drug year 2000. 3 The incidence of this tumour is increasresistance. Transfection studies have demonstrated ing. For example, there has been a 38% increase that MDR1 is responsible for the multi-drug resistance between 1974 and 1990 in the USA. 2 phenotype, although the function of MDR2 in The treatment of renal cell cancer has radically humans is uncertain. High levels of the MDR1 changed in the last decade, and these changes have protein, a 170 kDa cell-surface ATP-binding efflux brought significant hope to patients with this maligpump, are found in cells of the proximal renal nancy. Chemotherapy and hormonal treatments are tubules8 and the majority of renal cell cancers are given for metastatic renal cell cancer, but response most closely related to these cells immunophenotyprates are low at 5-10%, and the duration of response ically. A correlation has been found between is measured in months. In contrast, immunotherapy is P-glycoprotein expression and progression-free surrelatively successful with responses in up to 40% of vival in renal cell cancer.9 Although inhibitors of the patients. The importance of immunotherapy P-glycoprotein calcium efflux pump do not potentiate responses is that they may be durable.
the effects of chemotherapy, this may be because Oestrogens induce renal cancers in Syrian Golden dosages sufficient to have a biological effect are not hamsters, and this effect is abrogated by progestapossible in humans because of toxicity.6,10 gens.4 On the basis of this observation, a trial of Against this background of the failure of convenmedroxyprogesterone acetate was initiated in the tional treatments for renal cell cancer, the successes 1960s which showed a 27% response rate of 9 of immunotherapy have been welcomed by oncolomonths median duration.5 Unfortunately however, gists and embraced by their patients. This article this excellent result, a tribute to positive publication, reviews the current status of immunotherapy for has never been repeated, and progestagens have renal cell cancers. largely been abandoned as first-line therapy for advanced renal cell cancer.
In a similar fashion, chemotherapy has little effect in renal cell carcinoma. In phase II trials, even with Theoretical basis of immunotherapy the following wind of positive reporting, no single cytotoxic agent has produced a response rate Immunotherapy for cancer dates back to the turn of exceeding 10%. An overall response rate of just 6% the century to the use of Cooley's toxins. There are is reported in a review of 4093 patients enrolled clinical features of renal cell cancer that point to the importance of the host immune system in controlling into 83 chemotherapy trials between 1983 tumour growth, and the most significant is the laboratory studies have shown a dose response to IFNa observation of the spontaneous regression of metawith maximal responses at 18 mega U, these findings static disease that occurs more frequently in renal have not been reproduced in patients with cancer. cell cancer than in any other solid tumour. [11] [12] [13] [14] Currently the majority of patients are treated with The interferons months in the MPA arm.23 In the field of oncology, immunotherapy really began
The mechanism of anti-tumour activity for interferon with the use of partially purified interferons derived remains unclear. In vitro, interferons have a direct antifrom leukocytes (IFNa), fibroblasts (IFNb) and proliferative action on renal cell tumour cell lines. This lymphocytes (IFNc). The first report documenanti-proliferative activity is thought to be due to interting responses in advanced renal cell cancer with feron-induced expression of an RNA-dependent tyrospartially-purified leukocyte interferon appeared ine kinase that phosphorylates the a subunit of eIF-2, in 1983.19 Subsequent trials have described responses a translation initiation factor.24 In addition, interferons using both non-recombinant and recombinant interstimulate host lymphocytes and macrophages and ferons. Similar response rates are achieved with the upregulate MHC class I antigen expression. A third different recombinant IFNas available. Combining possible mechanism of action that has been proposed data from 29 studies of IFNa involving over 1000 for interferon is as an anti-angiogenesis agent. patients, the objective response rate was 12%,20 but
Resistance to interferon therapy may in part be due to the complete remission rate was only 2% and the the development of neutralizing antibodies.25 median response duration of those patients achieving IFNc has greater in vitro activity against renal cell a complete response, just 8 months.
carcinoma lines than either IFNa or IFNb. However, The optimal dosage schedule for IFNa remains conlaboratory activity does not match clinical data, and troversial. Initially, in a classical oncology investigatory similar clinical results are achieved to those with approach, phase I studies examined the highest treatother interferons, with a cumulative response rate of ment dosages possible. The interferons given in dosages 12% in 234 patients treated in 10 phase I/II trials.26 of up to 100 000 mega U, were profoundly toxic. In
Response rates for IFNc are lower in patients the mid 1980s, investigators backed off from highwith bulky disease who have not undergone dosage schedules, with the realization that maximal tolerable dosages did not equate with efficacy. Although nephrectomy.27
suggested high-and low-dose IL-2 confirmed that the highapproach to tumour immunotherapy called adoptive dose schedule was more cardiotoxic, and was also immunotherapy using autologous peripheral blood associated with thrombocytopenia and more infecmononuclear cells stimulated ex vivo with IL-2. tious episodes. There was no statistically significant At the NCI in the United States, Rosenberg demondifference in the response rates or complete remission strated that IL-2 alone and in combination with LAK rates between the high-and low-dose arms.34 cells decreased the size of pulmonary and hepatic As a result of these trials, treatment with IL-2 has metastases.28 In mouse tumour models, LAK cells been transformed and moved to an out-patient setwith IL-2 was more effective than IL-2 alone, and ting, where it can be given with little or no grade the combination, but not IL-2 alone, was active in III/IV toxicity. immunodeficient mice. The best responses in mice were achieved using the maximal tolerated dosages of both LAK cells and IL-2. Since very high doses of
Combination immunotherapy

IL-2 were necessary to generate LAK cells in vivo,
After the development of safe out-patient low-dose ex-vivo expansion was advocated. These findings in single-agent immunotherapy schedules for both IFNa animal models were the basis for a series of clinical and IL-2, investigators sought to develop combination studies which combined ex-vivo generated autoimmunotherapy. In animal models, the partnership logous LAK cells and maximal doses of IL-2. 29 between IFNa-induced upregulation of MHC expresThese phase I studies demonstrated activity of LAK sion and IL-2-induced T-lymphocyte and NK-cell cells with IL-2, but also profound toxicity, with the activation leads to a synergy of immunological and informal suggestion that the majority of patients anti-tumour effects.35-37 Initial studies in humans treated required ICU care because of the multisystem were encouraging,38 however, subsequent prospectcomplications of vascular leak syndrome. Now, ive randomized studies suggested that the proportion because mouse studies had shown that IL-2 alone of responses with the combination immunotherapy was active in immunocompetent mice and responses was no higher than with IL-2 alone.39-41 had been seen among some patients who were given Eventually a randomized study was organized, IL-2 alone, a randomized comparative study of IL-2 and the French Immunotherapy Group of the French with or without LAK cells resulted, which showed Federation of Cancer Centres have recently reported identical response rates. 30 the interim results of their CRECY study. They Ten trials of bolus high-dose intravenous IL-2 have randomly assigned 425 patients to receive one of been published which have enrolled a total of 537 three immunotherapy schedules: continuous intrapatients. The combined objective response rate is venous IL-2 infusion; subcutaneous IFNa; or a com-19%, with a median response duration of 22 bination of continuous infusional IL-2 and months.31 However, severe toxicity was associated subcutaneous IFNa. Results, reported so far only in with the treatment, due to vascular leak syndrome abstract form, have shown that the combination from bolus injections. The treatment-related mortality therapy was superior to either single agent as assessed with bolus IL-2 is 4%. 32 by response rate and event-free survival at one year, In the late 1980s, it began to emerge that the although the toxic death rate for the combination importance of the complete response to IL-2 was the arm was reported as 3.6% compared to 0.7% for durability of that response, which was in contrast to IFNa alone and 7.9% for IL-2 alone.42 any other treatment of renal cell cancer. This realization led to a persistence with IL-2, and investigations of ways of reducing the toxicity of bolus therapy.
Chemoimmunotherapy
The first step in this path was the investigation of the effects of continuous infusions of IL-2. A summary Efforts have been made to assess whether there is an of trials in 422 patients showed an objective response advantage in combining chemotherapy and immunorate of 14%. 33 therapy. Initially, interferon was combined with The next phase of development for IL-2 occurred 5-fluorouracil, as there is biochemical synergy, and response rates of 35% resulted. 43 More ambitious in the early 1990s. Although preclinical data had chemoimmunotherapy regimens including both IFNa will have to await results from a randomized comparison with IL-2. and IL-2 were devised, and in an initial trial, 35 patients with metastatic renal cell cancers were treated with alternating cycles of combination immunotherapy with IL-2 and IFNa and chemoimmuno-
Vaccination programmes
therapy with bolus 5-fluorouracil and IL-2. The regimen was administered on an out-patient basis.
Cancer cell vaccination therapy involves the treatment of patients with tumour cells that have been The overall response rate was 48%, and was without severe toxicity. 44 These results have been reproduced genetically modified to enhance the host immune response against established residual tumour masses. by one group45 but not by others. 46, 47 The protocols usually involve the isolation and culture of tumour cells from biopsies, followed by the transfection of established tumour cell lines in Cellular adoptive immunotherapy culture. The transfected autologous tumour cells are There has been further progress in the field of then irradiated prior to re-injection. For renal cell adoptive immunotherapy in the 1990s, mainly involcancers, transfection with cytokine genes has been ving studies of the effects of tumour-infiltrating advocated to induce a tumour-specific immune lymphocytes (TILs), which are lymphocytes extracted response. One early clinical trial randomized patients from tumour biopsies. LAK cell activity is thought to with localized disease to nephrectomy or nephrecbe NK-cell-mediated, but TIL are T cells that express tomy followed by immunization with irradiated autolboth helper (CD4+) and cytotoxic (CD8+) with the GM-CSF gene were used to vaccinate 16 and 33% in 48 patients.50 At UCLA, the response patients with advanced renal cell carcinoma and rates, median response duration and 3-year survival again T-cell-mediated delayed hypersensitivity was rates were higher in 58 patients treated with TIL/IL-2 observed, although only one patient had an objective than in patients who received IL-2 alone or in partial response.57 combination with IFNa.51 The benefits of TIL/IL-2 therapy over IL-2 alone are currently being investigated in a randomized study.
Conclusion
Immunotherapy is the most effective of the current Autolymphocyte therapy therapies available for metastatic renal cell cancer. Patients with a good performance status, a long Autolymphocyte therapy (ALT) aims to activate memory T cells by ex-vivo expansion of peripheral blood monodisease-free interval, and metastases in favourable sites have the best prognosis, and are most likely to nuclear cells with supernatants of anti-CD3 monoclonal-antibody-activated autologous peripheral blood benefit from immunotherapy. Patients with none of these clinical features have a poor chance of response lymphocytes and IL-2. Anti-CD3 only activates T cells previously exposed to antigen, and clonal expansion and should not be subjected to the prospect of treatment-related toxicity without the hope of benefit of these memory T cells is driven by IL-2. Prior to re-infusion, the cells are treated with cimetidine and from therapy. The results of MRC study confirm the benefits of immunotherapy over other treatment irradiated to destroy suppressor T cells. In a randomized trial that enrolled 90 patients, the addition of ALT modalities in metastatic renal cell cancers. However, which immunotherapy regimen is optimal remains to cimetidine produced a survival advantage compared with cimetidine alone,52 and this result has been controversial, although the CRECY study results favour the combination of IL-2 and IFNa given in confirmed in other centres.53, 54 The place of ALT in the clinical management of metastatic renal cell cancer low dosages subcutaneously. Future investigations
